tiprankstipranks
Beximco Pharmaceuticals Limited Sponsored GDR RegS (GB:BXP)
LSE:BXP
Holding GB:BXP?
Track your performance easily

Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP) Financial Statements

5 Followers

Beximco Pharmaceuticals Limited Sponsored GDR RegS Financial Overview

Beximco Pharmaceuticals Limited Sponsored GDR RegS's market cap is currently ―. The company's EPS TTM is p0.092; its P/E ratio is 3.93; and it has a dividend yield of 5.86%. Beximco Pharmaceuticals Limited Sponsored GDR RegS is scheduled to report earnings on January 29, 2025, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue$ 9.89B$ 9.79B$ 8.74B$ 8.96B$ 8.50B
Gross Profit$ 4.44B$ 4.42B$ 3.60B$ 4.05B$ 4.09B
EBIT$ 1.99B$ 2.19B$ 1.22B$ 1.87B$ 2.45B
EBITDA$ 1.99B$ 2.19B$ 1.35B$ 1.87B$ 2.45B
Net Income Common Stockholders$ 1.24B$ 1.45B$ 842.68M$ 1.10B$ 1.71B
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.25B$ 872.65M$ 1.17B$ 589.04M$ 1.18B
Total Assets$ 69.31B$ 67.47B$ 66.15B$ 65.15B$ 65.08B
Total Debt$ 11.50B$ 12.01B$ 12.37B$ 11.83B$ 11.04B
Net Debt$ 10.26B$ 11.14B$ 11.20B$ 11.24B$ 9.86B
Total Liabilities$ 23.59B$ 21.43B$ 21.51B$ 21.31B$ 22.28B
Stockholders Equity$ 41.72B$ 42.04B$ 40.60B$ 39.76B$ 38.66B
Cash Flow-
Free Cash Flow$ 997.78M$ 2.06M$ 148.92M$ 122.04M$ 836.17M
Operating Cash Flow-----
Investing Cash Flow$ -680.85M$ -630.27M$ -1.10B$ -165.83M$ -843.66M
Financing Cash Flow$ -641.49M$ -363.37M$ 384.60M$ -723.07M$ -501.02M
Currency in USD

Beximco Pharmaceuticals Limited Sponsored GDR RegS Earnings and Revenue History

Beximco Pharmaceuticals Limited Sponsored GDR RegS Debt to Assets

Beximco Pharmaceuticals Limited Sponsored GDR RegS Cash Flow

Beximco Pharmaceuticals Limited Sponsored GDR RegS Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis